In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) reported that Svlsf V, Llc. has picked up 2,579,490 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 2,579,490 representing a 26.6% stake in the company.
For those not familiar with the company, KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
A glance at Kalvista Pharmaceuticals Inc. (NASDAQ:KALV)’s key stats reveals a current market capitalization of 70.68 million based on 9.93 million shares outstanding and a price at last close of $7.16 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-04-14, Cha picked up 7,364 at a purchase price of $5.00. This brings their total holding to 4,204,562 as of the date of the filing.
On the sell side, the most recent transaction saw Renzi unload 10,000 shares at a sale price of $3.70. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.